Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Total Non-Current Liabilities (2019 - 2025)

Vaxcyte (PCVX) has 7 years of Total Non-Current Liabilities data on record, last reported at $317.1 million in Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 54.39% to $317.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $317.1 million, a 54.39% increase, with the full-year FY2025 number at $317.1 million, up 54.39% from a year prior.
  • Total Non-Current Liabilities reached $317.1 million in Q4 2025 per PCVX's latest filing, up from $205.4 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for PCVX hit a ceiling of $317.1 million in Q4 2025 and a floor of $40.2 million in Q4 2021.
  • A 5-year average of $92.4 million and a median of $54.0 million in 2021 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: dropped 22.11% in 2022, then skyrocketed 218.61% in 2023.
  • Tracing PCVX's Total Non-Current Liabilities over 5 years: stood at $40.2 million in 2021, then soared by 30.66% to $52.6 million in 2022, then surged by 218.61% to $167.4 million in 2023, then rose by 22.66% to $205.4 million in 2024, then surged by 54.39% to $317.1 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for PCVX at $317.1 million in Q4 2025, $205.4 million in Q4 2024, and $167.4 million in Q4 2023.